SUMMARY Specific double (D-DNA) and single stranded (S-DNA) deoxyribonucleic acid binding cells were demonstrated in the peripheral blood lymphocytes of patients with systemic lupus erythematosus (SLE) by rosette formation with antigen coated red blood cells. The proportion of DNA binding cells in the peripheral blood ofpatients with SLE was significantly higher than that found in a random population of healthy individuals. Significant numbers of D-and S-DNA binding lymphocytes were found in patients with active disease even when anti-DNA of fluorescent antinuclear antibodies disappeared. The specificity of the DNA binding cells was confirmed by inhibition experiments with D-or S-DNA. Spleen lymphocytes were also examined on one occasion and were found to contain a much higher level of DNA binding lymphocytes than the peripheral blood lymphocytes.
of the American Rheumatism Association for classification as SLE (Cohen et al., 1971) and from 1 patient with procainamide-induced SLE. Patients were either undergoing treatment or were during remission at the time of venepuncture. On 1 occasion splenic lymphocytes were also examined after the death of 1 of the patients.
LYMPHOCYTES
Lymphocytes were isolated on a Ficoll-Hypaque gradient (Boyum, 1968) and washed 3 times in cold Hanks's medium. The lymphocytes were suspended in either Tris buffered MEM or Hanks's medium with 5 % fetal calf serum (FCS) at a concentration of 10 x 106/ml.
DNA
Calf thymus DNA (Calbiochem. Lot 900007) was dissolved in phosphate-buffered saline (PBS), pH 7 3, at a concentration of 500 jig/ml. D-DNA was rendered single stranded by boiling for 15 min followed by rapid cooling. DNA solutions were kept at 40C.
COUPLING OF D-DNA AND S-DNA TO 0 RH POSITIVE RED BLOOD CELLS
The coupling ofeither D-DNA or S-DNA was carried out according to Clark et al. (1972) . lml of D-DNA or S-DNA (500 ,ug/ml) was mixed with 0 * 8 ml saline and 0w 1 ml chromium chloride (20 mg/ml). To this DNA binding lymphocytes in SLE 545 mixture 0 2 ml of 50% washed 0 Rh + RBC was added and mixed thoroughly for 5 min at room temperature. 5 ml of cold saline was added to stop the reaction, and the cells were washed 4 times in PBS and resuspended in Tris-MEM or Hanks's medium with 5 % FCS at a concentration of 2 x 108/ml.
The presence of coupled DNA was detected by passive haemagglutination with human SLE antiserum to D-and S-DNA: derivatisation was constant with each preparation, as ascertained by haemagglutination titres. A fresh sample of cells was prepared a day or two before each experiment. Donkey RBC were used on some occasions in the same procedures.
ROSETTE-FORMING CELLS (RFC)
Three sets of tubes were set up in each experiment, each containing a pellet of 106 lymphocytes (0 1 ml of the original suspension). 0 1 ml PBS was added to the first set and 04-ml antigen (D-or S-DNA, 500 jig/ml) was added to the second and third set, respectively as specificity controls, to saturate the receptors on the lymphocytes. After mixing, the tubes were kept 1 hour on ice, and then 0 -1 ml of D-or S-DNA coupled RBC (20 x 106 RBC) were added to each tube (Iymphocytes/RBC ratio of 1/20), followed by 0 * 1 ml of medium containing 5 % FCS. The contents of each tube were transferred to small plastic Beckman tubes, centrifuged immediately at 240 g at 40C for 5 min, and kept at 40C overnight. The cell pellets were gently resuspended with a Pasteur pipette, and an equal volume of 1 
Results

ANTINUCLEAR ANTIBODIES
The titre of fluorescent antinuclear antibodies ranged from 0 to more than 1/1600 (Table 1 ). In the microhaemagglutination test the titre of D-DNA coated RBC ranged from 1:6 to 1:16 and the titre of S-DNA ranged from 1:6 to 1 :100 (Table 1) . Little or no correlation was found between the severity of the clinical manifestations and the antibody titres as measured by either immunofluorescence or haemagglutination (Table 1) .
D-DNA ABC
In SLE patients 0 * 15 %-4 89 % of peripheral blood lymphocytes (mean 1 41 ± 0 40%) formed rosettes with D-DNA coupled RBC (Tables 1 and 2 ). The rosette formation was significantly inhibited by preincubation of the lymphocytes with D-DNA (mean inhibition 70 9 % ± 8 2 %). Lymphocytes of 2 out of 13 patients tested formed rosettes which could not be inhibited by D-DNA. One of these patients had SLE-like syndrome induced by procainamide (patient 8). The other (patient 6) had SLE manifestations which had started atypically at the age of 70. Preincubation of the lymphocytes (patient 6) with D-DNA resulted in unexplained enhancement of rosette formation. Normal controls had only 0 * 03°O4--66 % D-DNA ABC (mean 0*32% + 0O 1%), and most of these were only moderately inhibited by preincubation with D-DNA (mean inhibition 34 .2 % ± 9. 8 %). Both the level and the specificity (percent inhibition) of D-DNA ABC were higher in SLE patients than in normal controls (P<0 *02 and P<0 *001 respectively). No correlation was found between the titre of anti-D-DNA antibodies and the level of D-DNA ABC (Table 1) .
S-DNA ABC
Rosettes with S-DNA coupled RBC were formed by 0 07 %/-7 40% of peripheral blood lymphocytes (mean 2 *08 ± 0 38 % (Table 1) . Pretreatment of the lymphocytes with S-DNA markedly inhibited the rosette formation (mean inhibition 69 9 % ± 6 -7 %) in all except patient 6, in whom enhancement of rosette formation occurred. In normal controls S-DNA ABC ranged between 0 05 %-l *01 % (mean 0 29 ± 0.11 %) with lower inhibition by pretreatment with S-DNA (mean inhibition 35 6% ± 8 3%). The level of S-DNA ABC was significantly higher in SLE than in normal controls (P<0-01). No correlation was found between the titre of anti-S-DNA antibodies and the level of S-DNA ABC (Table 1) .
Several experiments were carried out to obtain some information on a number of variables which might possibly affect the results of the rosette tests, such as (1) variability within replicates, (2) effect of carrier red cell (donkey versus human), and (3) variability within lymphocyte samples taken at Table 2 the results were usually unaltered by any of these variables. In addition, no inhibition of D-and S-DNA ABC could be obtained by preincubating (Naor and Sulitzeanu, 1969) . Cytophilic antibodies or antigen-antibody complexes were unlikely to be involved in rosette formation by normal lymphocytes, as none of the normal donors had detectable antinuclear antibodies (by fluorescence and haemagglutination).
Since only one-third of the normal DNA ABC -ould be inhibited by DNA, it seemed reasonable .-at most of the normal ABC were reacting with --me membrane component of the RBC rather than th the DNA coating it. This was confirmed by the DNA binding lymphocytes in SLE 547
finding of lymphocytes rosetting with untreated allogenic and even autologous RBC in both normal persons and SLE patients. However, these rosettes could not be inhibited by either D or S-DNA nor by other unrelated proteins like BSA (Slavin and Sulitzeanu, unpublished) . Lymphocytes which can bind self components of the RBC membrane have already been described in mice (Siegel and Sherman, 1972) , rabbits (Baxley et al., 1973) , and man (Dewar et al., 1974; Bankhurst and Williams, 1975.) DNA ABC have been found in NZB/WF1 female mice which develop an autoimmune disease similar to SLE, with antinuclear antibodies. With the same rosette formation technique 1*3 %-8 5% of the mononuclear spleen cells showed binding of S-DNA coated to sheep RBC. In these experiments, too, 0*38 %-2 *0% of the splenocytes rosetted with normal uncoated sheep RBC (Clark et al., 1972) .
Native DNA ABC in SLE was demonstrated by autoradiography with 125I labelled DNA (Bankhurst and Williams, 1975) . The incidence of DNAbinding lymphocytes was 0 *40 ± 0 * 273 in 12 patients with active SLE in contrast to 0i 120 ± 0 048 and 0-048 ± 0 036 in 12 patients with inactive SLE and in normal persons, respectively.
In this study the incidence of DNA binding determined by rosetting was in the same range and occasionally higher. The difference may be due either to higher sensitivity of rosetting techniques as an indicator of DNA ABC or more likely to some interactions of the red cell membrane and macromolecules with lymphocyte receptors.
ABC specific for other antigens have also been studied in human peripheral blood lymphocytes by their ability to form rosettes with antigencoated RBC. After immunisation with the protein antigen Keyhole limpet haemocyanin (KLIH) 0 * 30 %/-7 -20 % of normal peripheral blood lymphocytes formed rosettes with KLH-coated RBC. There were 0 * 02 %/-0 * 24 % rosette-forming cells in the nonimmune individuals (Hersh and Dyre, 1974) . Rosette formation was also studied in human and experimental thyroiditis, which are good models of true autoimmune disorders (Perrudet-Badoux and Frei, 1969) . In human thyroiditis 0 15 %-97 8 % of peripheral blood lymphocytes rosetted with thyroglobulin-coated sheep red blood cells, whereas only 0o 05 -O -4% rosettes were demonstrated in other thyroid diseases. The rosettes could be inhibited by methotrexate. Thyroglobulin receptors were shown to appear after preincubation with trypsin. The number of rosettes did not correlate with the titre of circulating antibody, and the clinical picture correlated better with the rosette formation than with humoral antibodies (Perrudet-Badoux and Frei, 1969) .
The finding of high levels of D-DNA and S-DNA binding lymphocytes in SLE patients even during immunosuppressive therapy despite negative antinuclear antibodies (by immunofluorescence and haemagglutination) might be important. In autoimmune diseases the titration of circulating antibody is known to be of little diagnostic or prognostic value. However, in SLE, which is s classical immune complex disease, DNA-anti-DNA complexes play a major role in the pathogenesis of the vascular manifestations, predominantly the kidney. Therefore a decreasing titre of antinuclear antibodies is usually considered as an important parameter for evaluating the efficiency of the therapeutic means and/or remission. Nevertheless, many patients (case 1 being an example) deteriorate despite improvement of the laboratory parameters of disease, including the titre of antinuclear antibodies. As shown in this study, DNA binding lymphocytes can be demonstrated even when no anti-DNA antibody is detectable. It seems therefore that these ABC might be the memory cells for anti-DNAproducing lymphoplasmocytes. Quantitations of DNA-binding lymphocytes during various stages of SLE and in relation to therapy should be carried out to evaluate their possible prognostic implications. Maximal 'knock-out 'of anti-DNA memory cells with DNA ABC as a marker might be essential in order to achieve better remission in SLE.
Another point of interest was the finding of a much higher level of D-and S-DNA ABC in the spleen than in the blood of one SLE patient (4.1 % of D-DNA ABC and 9 4% of S-DNA ABC in the spleen versus O*72 % and 1*38 % in the blood, respectively). These data would suggest a role for the spleen as a potential reservoir of committed, activated lymphocytes in SLE. Further studies of SLE at the cellular level might contribute to better understanding of the disease. 
